We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
ADAG

Price
1.90
Stock movement down
-0.05 (-2.56%)
Company name
Adagene Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
89.55M
Ent value
38.07M
Price/Sales
219.55
Price/Book
1.58
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-24.30%
3 year return
-8.25%
5 year return
-
10 year return
-
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ADAG does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales219.55
Price to Book1.58
EV to Sales93.33

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count47.13M
EPS (TTM)-0.75
FCF per share (TTM)-0.45

Income statement

Loading...
Income statement data
Revenue (TTM)407.87K
Gross profit (TTM)-17.59K
Operating income (TTM)-36.82M
Net income (TTM)-32.94M
EPS (TTM)-0.75
EPS (1y forward)-0.72

Margins

Loading...
Margins data
Gross margin (TTM)-4.31%
Operating margin (TTM)-9026.88%
Profit margin (TTM)-8075.15%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash95.67M
Net receivables31.42K
Total current assets98.80M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets100.78M
Accounts payable3.37M
Short/Current long term debt20.79M
Total current liabilities39.52M
Total liabilities44.19M
Shareholder's equity56.59M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-20.06M
Capital expenditures (TTM)18.82K
Free cash flow (TTM)-20.08M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-58.20%
Return on Assets-32.68%
Return on Invested Capital-45.30%
Cash Return on Invested Capital-27.62%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open2.00
Daily high2.00
Daily low1.90
Daily Volume3K
All-time high29.60
1y analyst estimate9.64
Beta0.74
EPS (TTM)-0.75
Dividend per share-
Ex-div date-
Next earnings date3 Dec 2025

Downside potential

Loading...
Downside potential data
ADAGS&P500
Current price drop from All-time high-93.58%-3.04%
Highest price drop-96.96%-56.47%
Date of highest drop31 Oct 20229 Mar 2009
Avg drop from high-83.30%-11.04%
Avg time to new high365 days12 days
Max time to new high1094 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ADAG (Adagene Inc) company logo
Marketcap
89.55M
Marketcap category
Small-cap
Description
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Employees
138
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...